Bonspark 2200IU Nasal Spray is used in the treatment of post menopausal osteoporosis. It used to prevent bone loss due to osteoporosis (thinning of the bones) in women who have not had monthly periods for at least 5 years.
Use this medicine in the dose and duration as advised by your doctor. Check the label for directions before use. Insert the bottle tip into one nostril and close the other nostril. Direct the spray away from the cartilage diving the two sides of your nose and toward the sides of your nostril. As you spray, breath gently and keep the head upright. Repeat in the other nostril.
Bonspark 2200IU Nasal Spray is a calcitonin receptor agonist. It acts by suppressing the activity of osteoclasts, cells that cause destruction of bone, thereby strengthening the bones and minimizing the risk of fractures.
Bonspark 2200IU Nasal Spray may be unsafe to use during pregnancy. Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
Bonspark 2200IU Nasal Spray is safe to use during lactation.
Human studies have shown that either the drug does not pass into the breastmilk in significant amount or is not expected to cause toxicity to the baby. It should be wiped off thoroughly prior to nursing if it is being applied to the breast or nipple area.
It is not known whether Bonspark 2200IU Nasal Spray alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
There is limited information available on the use of Bonspark 2200IU Nasal Spray in patients with kidney disease. Please consult your doctor.
There is no data available. Please consult doctor before consuming the drug.
If you miss a dose of Bonspark 2200IU Nasal Spray, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
What were the side-effects while using Bonspark 2200IU Nasal Spray?
No Side Effect
How do you take Bonspark Nasal Spray?
With or without food
How much was the improvement?
Please rate Bonspark 2200IU Nasal Spray on price
What are you using Bonspark Nasal Spray for?
Post menopausal osteoporosis
Survey Participants: 2
“The following are the results of on-going survey on 1mg.com for Bonspark 2200IU Nasal Spray. These results only indicate the perceptions of the website users. Please base your medical decisions only on the advice of a doctor or a registered medical professional.”
Q. Is calcitonin a steroid hormone/ peptide hormone/ bisphosphonate/ thyroid hormone?
Calcitonin is not a steroid hormone or a bisphosphonate. It occurs naturally in the body and is commercially available in the polypeptide hormone
Q. Is calcitonin effective for osteoporosis?
Calcitonin is a naturally occurring thyroid hormone which is used to prevent and to treat thinning and weakening of the bone (osteoporosis) in post-menopausal women
Q. Does calcitonin stimulate osteoclasts/ Inhibit osteoblast activity/ stimulate bone growth?
Osteoclast is a type of bone cell which carries out dissolution and absorption of bone. Calcitonin is a naturally occurring hormone secreted by thyroid gland in the body, which stops the activity of osteoclasts, thereby stopping bone removal by the osteoclasts. Whether calcitonin stimulates or promotes the bone formation or resorption by the osteoblasts is uncertain
Q. Does calcitonin cause cancer?
Long term treatment with calcitonin for osteoporosis and osteoarthritis has shown an increase in the risk of cancer in clinical trials
Q. Does calcitonin increases calcium levels?
Calcitonin does not increase calcium levels. It is a naturally occurring hormone secreted by the thyroid gland in the body, which is used to reduce high calcium levels in the blood (hypercalcemia) due to cancer
Q. Does calcitonin decreases phosphate?
Yes, calcitonin decreases phosphate resorption by direct action on the kidney.
Information last updated by Dr. Varun Gupta, MD Pharmacology on 8th Mar 2017.